FDA Approved: BANZEL — Supplemental Application (Eisai Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BANZEL (rufinamide) submitted by Eisai Inc., updating/expanding its label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lennox-gastaut Syndrome

Drugs mentioned

• Banzel (rufinamide)

Snippet

SUPPL AP for BANZEL (RUFINAMIDE)